Dr. Andrew Hendifar (@DrHendifar) header
Dr. Andrew Hendifar (@DrHendifar) profile picture

I am a physician and scientist working to develop new medications for gastrointestinal malignancies -- particularly pancreatic cancer and neuroendocrine tumors.

Los Angeles
Joined May 2013
Photo by Dr. Andrew Hendifar (@DrHendifar)Photo by Dr. Andrew Hendifar (@DrHendifar)Photo by Dr. Andrew Hendifar (@DrHendifar)Photo by Dr. Andrew Hendifar (@DrHendifar)Photo by Dr. Andrew Hendifar (@DrHendifar)Photo by Dr. Andrew Hendifar (@DrHendifar)Photo by Dr. Andrew Hendifar (@DrHendifar)Photo by Dr. Andrew Hendifar (@DrHendifar)Photo by Dr. Andrew Hendifar (@DrHendifar)Photo by Dr. Andrew Hendifar (@DrHendifar)
Dr. Andrew Hendifar retweeted
Replying to @AACI_Cancer
@AACI_Cancer recently highlighted 2 @CedarsSinai studies ➡️ our high-dose L-Gln phase I trial @NatureCancer & physical activity benefit on fatigue & #QoL in #CRC @JNCCN by Dr. Figueiredo & ⭐️fellow now @cityofhope #GIonc faculty @LouisaLiu131 aaci-cancer.org/aaci-update-… @OncoAlert
4
1
10
600
Dr. Andrew Hendifar retweeted
1/🧵 IITs/ISTs are often a labor of love. Proud to share that our phase I GlutaPanc trial testing the feasibility of pairing @FDA approved high-dose L-glutamine (L-Gln) + #1L gem/nab-paclitaxel (GA) in #mPDAC was published in @NatureCancer nature.com/articles/s43018-0… @OncoAlert – at Beverly Hills, CA
11
28
6
70
10,128
Dr. Andrew Hendifar retweeted
Until now, physicians using AI in clinic had to assemble the patient’s context themselves. Allergies, comorbidities, medications, prior procedures, copy-pasted in from the chart. Today we’re announcing a partnership with @CedarsSinai. OpenEvidence now works directly inside Epic, drawing on the patient’s full record and interpreting the medical literature through the lens of that specific patient. Cedars-Sinai is the first academic health system to deploy patient-aware clinical intelligence at enterprise scale. The clinician asks a complex question in natural language. The answer reflects both the best available evidence and the patient in front of them. Patient data is never stored after the clinical session or used for any other purpose.
50
217
80
1,109
1,002,778
Dr. Andrew Hendifar retweeted
Attention to 2026 ASCO Gastrointestinal Cancers Symposium attendees! ‼️ Check out poster L8 at Poster Session B today at #GI26 to learn about an #AI biomarker that is predictive of beneficial first-line chemo regimens for patients with #pancreaticcancer. 🧬 Presented by PanCAN Scientific and Medical Advisory Board (SMAB) Member and Scientific Advisor of @ValarLabs, @DrHendifar. Data from PanCAN's Know Your Tumor program from our SPARK platform was used as a validation dataset in this important study. asco.org/abstracts-presentat…
1
7
15
531
Dr. Andrew Hendifar retweeted
“Use of a computational histology artificial intelligence-powered predictive biomarker for chemotherapy selection in advanced pancreatic cancer patients from a multi-institutional cohort including two prospective studies.” Research by: @DrHendifar, @VisweshKrishna, @BarbaraGrnwald, @mnoel3232, @PancPathologist, Jennifer J. Knox  and others at @ASCO #GI26. @PanCAN
1
3
209
Dr. Andrew Hendifar retweeted
Real-world analysis in @JCOPO_ASCO of a large @PanCAN @Perthera #KnowYourTumor cohort ➡️ effects of #KRAS variants on survival and therapy response in #PDAC led by @DrHendifar @DrArsenOsipov @SriGaddamMD and team @CedarsSinai @MPishvaian ascopubs.org/doi/10.1200/PO-… @OncoAlert
2
9
35
3,418
Dr. Andrew Hendifar retweeted
Huge congrats to @CSCancerCenter 2nd yr heme/onc fellow Dr. Louisa Liu for her 2025 @ConquerCancerFd #YIA 🙌❗️❗️Way to represent @CedarsSinai. Proud to serve as her mentor for this award. As a former class of 2022 @ASCO #CCF #CDA recipient, I know how impactful this award will be
Congratulations to this year’s class of Conquer Cancer grant and award recipients! Are you one of them? Tell us in the comments! We can't wait to celebrate with you at #ASCO25. Full list of recipients: brnw.ch/21wSR0A @ASCO
1
8
29
4,729
Morning run with ⁦@NoahMerrin⁩, And Hyung Kim ⁦@CedarsSinai⁩ 2025 Faculty retreat. Stopping for pics is the only way to keep up with Zab Mosenifar. ⁦⁩ ⁦⁦@CedarsSinaiMed⁩
1
1
14
466
Dr. Andrew Hendifar retweeted
We have compared the performance ctDNA by Natera vs. imaging in curatively resected colorectal cancer on surveillance. Signatera missed 31% of recurrences (+ imaging and negative Signatera). Largest study of comparative strategies. jamanetwork.com/journals/jam…
7
39
7
122
30,009
Understanding and Treating Pancreatic Cancer Cachexia | Blog | AACR - goo.gl/alerts/gCyikP #GoogleAlerts. Addressing cancer associated weight loss will become a pillar of cancer care in the near future. #PancreaticCancer @CSCancerCenter
1
3
310
As this novel approach to improving weight and performance continues to develop, cancer patients will finally get an opportunity to look and feel like their “old selves”. A great moment for cancer care. @myESMO @NEJM @pfizer
Presented at #ESMO24: The monoclonal antibody ponsegromab increased weight, improved appetite, and allowed an increase in physical activity in patients with cancer who had lost more than 5% of body weight in the past 6 months. Full trial results: nej.md/3XE645a
3
12
1,010
Dr. Andrew Hendifar retweeted
🚨🚨Hot off the press @NEJM In a randomized Ph II Ponsegromab, an anti-GDF15 mAB, increased weight gain, overall physical activity and reduced cachexia symptoms in patients with #cachexia and ⬆️ GDF-15 nejm.org/doi/full/10.1056/NE…
7
70
12
208
38,358
High frequency of germline variants in CFTR identified in PDAC patient... sciencedirect.com/science/ar…. interesting finding in pdac patients who had testing for pancreatitis associated germline variants. @DrArsenOsipov
2
5
521
Dr. Andrew Hendifar retweeted
Abstract submissions are now open for the @AACR special conference on #PancreaticCancer #AACRPan24 Outline of proposed program below: aacr.org/meeting/aacr-specia…
2
16
1
57
16,734